Compensated Awareness Post View
Disclaimer
International Stem Cell Corp. (ISCO) CSO to Present at Upcoming Rodman and Renshaw
International Stem Cell (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, this morning announced that company board member and Chief Scientific Officer Ruslan Semechkin, PhD, will present at the upcoming Rodman and Renshaw 17th Annual Global Investment Conference in New York.
Dr. Semechkin will provide a company overview and update on development of clinical and research programs when he takes the floor Wednesday, September 9, 2015, at 3 p.m. ET.
The company advises that you contact the conference organizers if you have an interest in attending the conference or if you would like to arrange a meeting with International Stem Cell’s management team.
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™.
International Stem Cell also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).
For more information visit www.internationalstemcell.com
AI
